Enhancing retention and efficacy of cardiosphere-derived cells administered after myocardial infarction using a hyaluronan-gelatin hydrogel

Rachel R uckdeschel Smith, Eduardo Marbán, Linda Marbán

Research output: Contribution to journalArticle

Abstract

Cardiosphere-derived cells (CDCs) are under clinical development and are currently being tested in a clinical trial enrolling patients who have undergone a myocardial infarction. CDCs are presently administered via infusion into the infarct-related artery and have been shown in early clinical trials to be effective agents of myocardial regeneration. This review describes the administration of CDCs in a hyaluronan-gelatin hydrogel via myocardial injection and the subsequent improvements in therapeutic benefit seen in animal models. Development of a next generation therapy involving the combination of CDCs and hydrogel is discussed.

Original languageEnglish (US)
JournalBiomatter
Volume3
Issue number1
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Hydrogel
Hyaluronic Acid
Gelatin
Myocardial Infarction
Clinical Trials
Regeneration
Animal Models
Arteries
Injections
Therapeutics

Keywords

  • ALLSTAR trial
  • CADUCEUS trial
  • cardiosphere-derived cells
  • hyaluronan-gelatin hydrogel
  • myocardial infarction

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Enhancing retention and efficacy of cardiosphere-derived cells administered after myocardial infarction using a hyaluronan-gelatin hydrogel. / Smith, Rachel R uckdeschel; Marbán, Eduardo; Marbán, Linda.

In: Biomatter, Vol. 3, No. 1, 01.01.2013.

Research output: Contribution to journalArticle

@article{585742392473400393c2ee3655907d30,
title = "Enhancing retention and efficacy of cardiosphere-derived cells administered after myocardial infarction using a hyaluronan-gelatin hydrogel",
abstract = "Cardiosphere-derived cells (CDCs) are under clinical development and are currently being tested in a clinical trial enrolling patients who have undergone a myocardial infarction. CDCs are presently administered via infusion into the infarct-related artery and have been shown in early clinical trials to be effective agents of myocardial regeneration. This review describes the administration of CDCs in a hyaluronan-gelatin hydrogel via myocardial injection and the subsequent improvements in therapeutic benefit seen in animal models. Development of a next generation therapy involving the combination of CDCs and hydrogel is discussed.",
keywords = "ALLSTAR trial, CADUCEUS trial, cardiosphere-derived cells, hyaluronan-gelatin hydrogel, myocardial infarction",
author = "Smith, {Rachel R uckdeschel} and Eduardo Marb{\'a}n and Linda Marb{\'a}n",
year = "2013",
month = "1",
day = "1",
doi = "10.4161/biom.24490",
language = "English (US)",
volume = "3",
journal = "Biomatter",
issn = "2159-2527",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - Enhancing retention and efficacy of cardiosphere-derived cells administered after myocardial infarction using a hyaluronan-gelatin hydrogel

AU - Smith, Rachel R uckdeschel

AU - Marbán, Eduardo

AU - Marbán, Linda

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Cardiosphere-derived cells (CDCs) are under clinical development and are currently being tested in a clinical trial enrolling patients who have undergone a myocardial infarction. CDCs are presently administered via infusion into the infarct-related artery and have been shown in early clinical trials to be effective agents of myocardial regeneration. This review describes the administration of CDCs in a hyaluronan-gelatin hydrogel via myocardial injection and the subsequent improvements in therapeutic benefit seen in animal models. Development of a next generation therapy involving the combination of CDCs and hydrogel is discussed.

AB - Cardiosphere-derived cells (CDCs) are under clinical development and are currently being tested in a clinical trial enrolling patients who have undergone a myocardial infarction. CDCs are presently administered via infusion into the infarct-related artery and have been shown in early clinical trials to be effective agents of myocardial regeneration. This review describes the administration of CDCs in a hyaluronan-gelatin hydrogel via myocardial injection and the subsequent improvements in therapeutic benefit seen in animal models. Development of a next generation therapy involving the combination of CDCs and hydrogel is discussed.

KW - ALLSTAR trial

KW - CADUCEUS trial

KW - cardiosphere-derived cells

KW - hyaluronan-gelatin hydrogel

KW - myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=84888064939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888064939&partnerID=8YFLogxK

U2 - 10.4161/biom.24490

DO - 10.4161/biom.24490

M3 - Article

C2 - 23538511

AN - SCOPUS:84888064939

VL - 3

JO - Biomatter

JF - Biomatter

SN - 2159-2527

IS - 1

ER -